ArticlePloS one2025
Testing policies during an epidemic: An economic analysis.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Optimal prevention and control strategy of infectious disease: Cost-effectiveness analysis based on a modified dynamic model with economic loss.Infectious Disease Modelling · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
I build a stochastic epidemiological model with production and endogenous responses to the epidemic to compare different testing policies to isolate and quarantine the infectious: voluntary tests, random screenings and contact tracing. To increase the number of screened individuals at given testing capacity, I also allow for the use of group testing. Contact tracing with group testing is the best testing policy unless in case of: very contagious diseases, socially dense countries, high test costs and limited testing capacity. The gains include a lower mortality, a smaller output loss, and lower peaks of infections and hospitalizations. I show that sophisticated tracing technologies are not needed to achieve these gains.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.